1. Home
  2. LTRN vs COCH Comparison

LTRN vs COCH Comparison

Compare LTRN & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.54

Market Cap

46.8M

Sector

Health Care

ML Signal

HOLD

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.76

Market Cap

51.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRN
COCH
Founded
2013
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
46.8M
51.0M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LTRN
COCH
Price
$2.54
$0.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
71.6K
154.6K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
18.65
17.45
EPS
N/A
N/A
Revenue
N/A
$241,000.00
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.11
52 Week Low
$1.11
$0.36
52 Week High
$4.70
$1.89

Technical Indicators

Market Signals
Indicator
LTRN
COCH
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LTRN
COCH

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: